

ERRATUM

DNA base adducts in urine and white blood cells of cancer patients receiving combination chemotherapies which include *N*-methyl-*N*-nitrosourea

V. Prevost, A. J. Likhachev, N. A. Loktionova, H. Bartsch, C. P. Wild, O. I. Kazanova, A. I. Arkhipov, M. L. Gershanovich and D. E. G. Shuker, *Biomarkers*, **1**, 244–251.

We regret that on p. 247 figure 2 was printed incorrectly. Figure 2 is printed correctly below:




Figure 2. Dose–response for 3-MeAde excretion as a function of administered dose of MNU (mg m^{-2}). The values used for this correlation were based on urine samples which were collected at the beginning of treatment cycles when no other methylating agent had been administered. The values for 3-MeAde excretion at a zero dose of MNU are background values for each patient in urine samples collected immediately prior to treatment.